Zacks Analyst Blog Highlights: Avici Systems, Grupo Aeroportuario and Amylin Pharmaceuticals.

CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Avici Systems (Nasdaq: AVCI), Grupo Aeroportuario del Sureste (NYSE: ASR) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN).

See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673.

Here are highlights from Friday's Analyst Blog:

Slight Bump for Sell-Rated Avici

Although strong end-of-life router sales are driving better-than-expected revenue, our long-term outlook for Avici Systems (Nasdaq: AVCI) remains unchanged. We believe Soapstone offers a unique product and are encouraged by its compatibility with Nortel and Extreme, however we expect revenues to ramp slowly.

Six months from now, investors will likely be concerned about a lack of visibility into revenue growth from software. As such, we maintain a Sell rating on the shares with a slightly higher six-month price target of $7.50 to account for a higher cash balance.

Third quarter results were actually below our expectations, but the company expects to make this up in the fourth quarter. Our price target looks out six months, at which point product revenue for router sales in 2007 will be irrelevant to the company's valuation. Once router sales are complete, the stock should begin to trade on its current cash position, plus the value of a call option for the Soapstone business.

Grupo Aeroportuario Hits Oil Slick

We are changing our current recommendation on Grupo Aeroportuario del Sureste, S.A. de C.V. (NYSE: ASR) from Buy to Hold. Second quarter results were positive, with strong commercial revenues and positive passenger traffic. The outlook for the third quarter remains positive. The company has a long history of impressive results and strong cash flow.

However, the continued appreciation in the price of oil in the last few weeks coupled with a less benign economic environment in the U.S. is a huge short-term concern. In fact, since the U.S. Federal Reserve began to cut interest rates some weeks ago, oil has been appreciating almost on a daily basis, now getting to US$90 per barrel.

We believe the higher oil prices could undermine the end of the year tourist season in Cancun and Cozumel. Finally, the less positive economic environment in the U.S. as a result of the sub-prime mortgage system crisis, may affect the

Mexican economy in the following quarters since both economies have very strong ties.

Amylin Upgraded to a Hold

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) is engaged in the discovery, development and commercialization of potential drug candidates for the treatment of diabetes, obesity and Cardiovascular diseases. The top-line is being driven by sales of two diabetes drugs, Byetta and Symlin. Sales of both drugs have disappointed over the past several quarters, but the Amylin story is tied to the success or failure of phase III potential blockbuster, exenatide LAR.

Data on LAR is expected in the next month or so. At this time we are optimistic that the data will be positive, but the valuation on Amylin is not attractive. The stock is trading at 18x our 2011 EPS estimate, well above the peer-group of 12x, and that estimate assumes LAR posts sales over $1 billion.

The odds favor that LAR will demonstrate superiority to Byetta in this non-inferiority 30-week trial. We believe that has the potential to give the shares a pop upward towards $50. However, Amylin is an extremely expensive stock at this level, and even if we assume the most bullish forecast for LAR sales in 2011 north of $1 billion, we still only get to just over $2.50 in EPS. That puts the shares trading at 18x 2011 EPS.

We would avoid the name. We are upgrading our rating on Amylin from Sell to Hold, and raising our price target to $50 per share. Despite our increase in rating, we still do not like the stock at this level for investors. The key reason for our upgrade is the impending data on exenatide LAR.

See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

The performance of the Zacks Rank portfolios shown above for annual and year-to-date periods are the linked monthly total returns (price changes + dividends) of equal weighted hypothetical portfolios, consisting of those stocks with the indicated Zacks Rank, assuming monthly rebalancing and zero transaction costs. These are not the returns of actual portfolios. The hypothetical portfolios were created at the beginning of each month from Jan 1988 forward based on the values of the Zacks Rank available to Zacks' clients before the beginning of each month. The portfolios created monthly from 1988 through September 2006 exclude ADRS and are comprised of stocks that have the indicated Zacks Rank and were covered by at least two analysts at the time of the stocks inclusion in the portfolio. Starting in October 2006 and going forward, the portfolios are comprised of all stocks with the indicated Zacks Rank and do not exclude ADRs, which is more reflective of the list of stocks that customers will find on the Zacks web sites. 2007 returns are for the period of Jan 1 - Jun 30, 2007. These performance numbers have been audited from 1995 through 2003 by Autschuler Melovan, a division of American Express Financial.